Results 21 to 30 of about 2,496,873 (280)

Haematopoietic development and immunological function in the absence of cathepsin D [PDF]

open access: yes, 2007
Background: Cathepsin D is a well-characterized aspartic protease expressed ubiquitously in lysosomes. Cathepsin D deficiency is associated with a spectrum of pathologies leading ultimately to death.
Calogero Tulone   +17 more
core   +1 more source

Genetically Corrected iPSC-Derived Neural Stem Cell Grafts Deliver Enzyme Replacement to Affect CNS Disease in Sanfilippo B Mice

open access: yesMolecular Therapy: Methods & Clinical Development, 2018
Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB [MPS IIIB]) is a lysosomal storage disorder primarily affecting the brain that is caused by a deficiency in the enzyme α-N-acetylglucosaminidase (NAGLU), leading to intralysosomal accumulation ...
Don Clarke   +7 more
doaj   +1 more source

A block of autophagy in lysosomal storage disorders [PDF]

open access: yesHuman Molecular Genetics, 2007
Most lysosomal storage disorders (LSDs) are caused by deficiencies of lysosomal hydrolases. While LSDs were among the first inherited diseases for which the underlying biochemical defects were identified, the mechanisms from enzyme deficiency to cell death are poorly understood.
SETTEMBRE C   +9 more
openaire   +5 more sources

Mitochondrial Dysfunction in Lysosomal Storage Disorders [PDF]

open access: yesDiseases, 2016
Lysosomal storage diseases (LSDs) describe a heterogeneous group of rare inherited metabolic disorders that result from the absence or loss of function of lysosomal hydrolases or transporters, resulting in the progressive accumulation of undigested material in lysosomes.
Mario De la Mata   +8 more
openaire   +4 more sources

Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders

open access: yesMolecular Genetics and Metabolism Reports, 2018
Totally implantable vascular access devices (TIVADs) are commonly used in conjunction with enzyme replacement therapy (ERT) for lysosomal storage disorders (LSDs).
Christian J. Hendriksz   +4 more
doaj   +1 more source

Redefining GBA gene structure unveils the ability of Cap-independent, IRES-dependent gene regulation

open access: yesCommunications Biology, 2022
The cell type-specific expression of the glucocerebrosidase gene, associated with the lysosomal storage disorder called Gaucher disease, is linked to cis- and trans-regulatory transcriptional and translational mechanisms.
Keiko Miyoshi   +4 more
doaj   +1 more source

A mouse model for fucosidosis recapitulates storage pathology and neurological features of the milder form of the human disease

open access: yesDisease Models & Mechanisms, 2016
Fucosidosis is a rare lysosomal storage disorder caused by the inherited deficiency of the lysosomal hydrolase α-L-fucosidase, which leads to an impaired degradation of fucosylated glycoconjugates.
Heike Wolf   +8 more
doaj   +1 more source

Human INCL fibroblasts display abnormal mitochondrial and lysosomal networks and heightened susceptibility to ROS-induced cell death.

open access: yesPLoS ONE, 2021
Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a pediatric neurodegenerative disorder characterized by progressive retinal and central nervous system deterioration during infancy.
Bailey Balouch   +4 more
doaj   +1 more source

Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease – a new type of neuronal ceroid lipofuscinosis (CLN15)?

open access: yesActa Neuropathologica Communications, 2018
Homozygous mutation of TBC1 domain-containing kinase (TBCK) is the cause of a very recently defined severe childhood disorder, which is characterized by severe hypotonia, global developmental delay, intellectual disability, epilepsy, characteristic ...
Stefanie Beck-Wödl   +8 more
doaj   +1 more source

Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism

open access: yesEMBO Molecular Medicine, 2021
This work employs adult polyglucosan body disease (APBD) models to explore the efficacy and mechanism of action of the polyglucosan‐reducing compound 144DG11.
Or Kakhlon   +21 more
doaj   +1 more source

Home - About - Disclaimer - Privacy